Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea · Delayed Price · Currency is KRW 1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Revenue
Kainos Medicine had revenue of 322.20M KRW in the quarter ending September 30, 2025, with 58.22% growth. This brings the company's revenue in the last twelve months to 938.87M, up 51.41% year-over-year. In the year 2024, Kainos Medicine had annual revenue of 590.37M with 120.85% growth.
Revenue (ttm)
938.87M
Revenue Growth
+51.41%
P/S Ratio
37.87
Revenue / Employee
n/a
Employees
n/a
Market Cap
35.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.37M | 323.05M | 120.85% |
| Dec 31, 2023 | 267.31M | 137.29M | 105.59% |
| Dec 31, 2022 | 130.02M | -1.53B | -92.18% |
| Dec 31, 2021 | 1.66B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 31.12B |
| ADBiotech | 14.57B |
| Eutilex.Co.,Ltd | 10.54B |
| NGeneBio | 9.98B |
| MOA Life Plus | 9.80B |
| EyeGene | 4.10B |
| SCM Lifescience | 1.54B |
| Aptamer Sciences | 1.08B |